Mayne shares debut after split

Mayne Group's demerger took effect on the Australian sharemarket yesterday with its domestic healthcare business, Symbion Health, outperforming its new global pharmaceutical company, Mayne Pharma.

Symbion put on 19.5Ac to A$3.16 and Mayne was trading at A$2.85.